Maynard Um
-
-
-
-
-
-
-
CorMedix (CRMD) PT Lowered to $16 at Truist Securities
-
-
-
-
-
-
-
CorMedix (CRMD) PT Lowered to $21 at RBC Capital, 'we would be buyers'
-
-
-
-
-
-
-
CorMedix (CRMD) Tops Q2 EPS by 12c, Beats on Revenue
-
-
-
-
-
-
-
Truist on CorMedix (CRMD): 'News Better Than Expected'
-
-
-
-
-
-
-
Rodman & Renshaw Reiterates Buy Rating on CorMedix (CRMD), PT $20, 'weakness today is likely overdone'
-
-
-
-
-
-
-
CorMedix (CRMD) Tops Q3 EPS by 6c
-
-
-
-
-
-
341,965 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

